Study of the Effects of Pomegranate Tablets on Enlarged Prostates

NCT ID: NCT00381108

Last Updated: 2010-01-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-09-30
• Study Completion Date: 2010-06-30

Brief Summary

To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.

Detailed Description

Patients with newly diagnosed benign prostatic hyperplasia (BPH) will be recruited from the urology clinic at UCI medical center for this study as indicated in section 4. Once recruited, patients will be randomized into two groups - placebo and pomegranate tablets.

Prior to randomization, there will be a 6 week run-in period in which the basal parameters will be established. The basal parameters include a complete history and physical exam including an AUA symptom questionnaire and men's sexual health questionnaire, urine culture, urinalysis, PSA, serum chemistry (sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose), serum free testosterone, serum dihydrotestosterone, maximum urinary flow rate (Qmax), post void residual bladder volume, and prostate volume measurement via Trans-rectal ultrasound. Then patients will be randomized either to the study group or to the control group using a random number generator. All of the study subjects will be counseled to take one capsule daily in the morning and not to consume any other prostate supplements, or other forms of medical or herbal therapy for BPH.

Patients will be asked to come in every 2 months for the following tests and questionnaires to be administered:

1. AUA Symptoms Score sheet

2. Men's Sexual Health Questionnaire

3. Urine culture

4. Urinalysis

5. PSA

6. Serum chemistry (sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose)

7. Serum free testosterone

8. Serum 5-dihydrotestosterone

9. Maximum urinary flow rate (Qmax)

10. Post void residual check

11. Prostate volume measurement via Trans-rectal ultrasound

Maximum blood volume that will be drawn for each blood draw is 10 ml (2 table spoon), and the maximum blood draws per patient is 3 per person if there is no crossover and 6 if there is a crossover. Prior to all blood draw, patients will be asked to refrain from sexual intercourse for at least 48 hrs.

Patients with severe BPH (AUA symptom score 20 and above) or those already on other forms of medical therapy such as prescription finasteride, terazosin, or tamsulosin, propecia (for hair loss) or have any history of prostate surgery are not eligible to participate in this study. Also, patients who are taking non prescription supplements such as Saw Palmetto, B-sitosterol, vitamin E, quercetin, will not be included in the study. One group (n = 10) will take the pomegranate tablet. Group 2 (n = 10) will take 1 placebo tablet in the morning daily. Both pomegranate tablets and placebo will be provided by the Pomegranate Health Company.

Prior to randomization, there will be a 6-week run-in time because voiding parameters are notoriously variable. During this run-in time, patients will be asked to return to clinic every two weeks to measure maximum urinary flow and post-void residual bladder volume.

After a six-month period, each subject will be crossed over individually from placebo to active treatment, and from active treatment to placebo. The total anticipated timeline for the study is 12 months.

If early termination from the study is requested a final evaluation will be given. The final evaluation of the study will entail a standard office visit with blood collection and final AUA symptoms score and Men's sexual health questionnaire, and a transrectal ultrasound of the prostate measuring the same parameters as in the previous office visits. Subsequently, recommendations will be made by a urologist regarding the standard treatment options for BPH.

Conditions

Benign Prostatic Hyperplasia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Pomegranate Tablet

Group Type: EXPERIMENTAL

Pomegranate Tablet

Intervention Type: DRUG

Two tablets, twice daily.

Placebo Tablet

Group Type: PLACEBO_COMPARATOR

Placebo Tablet

Intervention Type: DRUG

Two tablets, twice daily.

Interventions

Placebo Tablet

Two tablets, twice daily.

Intervention Type: DRUG

Pomegranate Tablet

Two tablets, twice daily.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18 years of age or older
• Clinically diagnosed with mild to moderate BPH (AUA symptom score <20)

Exclusion Criteria

• Patient with severe BPH (AUA symptom score >21)
• Currently using any other forms of medical therapy, prescription finasteride, terazosin, tamsulosin or propecia (for hair loss).
• Prior Transurethral resection of the prostate (TURP).
• Using non-prescription supplements such as Saw Palmetto, B-sitosterol, vitamin E, and quercetin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Pomegranate Health

INDUSTRY

Sponsor Role: collaborator

Jarrow Pharmaceuticals

UNKNOWN

Sponsor Role: collaborator

University of California, Irvine

OTHER

Sponsor Role: lead

Responsible Party

University of California, Irvine

Principal Investigators

Leland Ronningen, MD

Role: PRINCIPAL_INVESTIGATOR

UCIMC Department of Urology

Locations

VA Long Beach

Long Beach, California, United States

University of California, Irvine-Department of Urology

Orange, California, United States

Countries

United States

Other Identifiers

2005-4373

Identifier Type: -

Identifier Source: org_study_id